Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma

• Published in: Clinical cancer research Vol. 28; no. 9; pp. 1896 - 1910
• Main Authors: Chen, Shuling, Xie, Yubin, Cai, Yuhong, Hu, Huanjing, He, Minghui, Liu, Lijuan, Liao, Changyi, Wang, Yuanqi, Wang, Jianping, Ren, Xiaoxue, Zeng, Qianwen, Peng, Hong, Shen, Shunli, Li, Shaoqiang, Li, Dongming, Lai, Jiaming, Peng, Baogang, Ren, Jian, Kuang, Ming, Peng, Sui
• Format: Journal Article
• Language: English
• Published: United States 01.05.2022
• Subjects: Bile Duct Neoplasms - genetics; Bile Duct Neoplasms - pathology; Bile Ducts, Intrahepatic - pathology; Biomarkers, Tumor - genetics; Cholangiocarcinoma - genetics; Cholangiocarcinoma - pathology; Humans; Prognosis; Transcriptome; Whole Exome Sequencing
• DOI: 10.1158/1078-0432.CCR-21-1157
• ISSN: 1078-0432; 1557-3265

Targeted therapy and immunotherapy are transforming the treatment approach for intrahepatic cholangiocarcinoma (ICC). However, little is known about the intertumor heterogeneity (ITH) of multifocal ICC and its impacts on patient response to these treatments. We aimed to characterize the immunogenomic and epigenomic heterogeneity of multifocal ICC to guide treatment decision making. We obtained 66 tumor samples from 16 patients with multifocal ICC and characterized the tumor and immune heterogeneity using whole-exome sequencing, bulk and single-cell RNA sequencing, methylation microarray, and multiplex immunostaining. Patients were divided into high- or low-ITH groups according to the median ITH index. Two independent cohorts were used to validate findings. Responses to anti-PD-1 therapy were assessed. Multifocal ICC presented considerable intertumor genomic, transcriptional, and epigenomic heterogeneity within a patient in high ITH group. The immune profile among multiple tumors within a patient was relatively less heterogeneous in high- or low-ITH group, and consistent responses of multiple tumors to anti-PD-1 immunotherapy were observed. Unsupervised clustering of immune markers identified one low and one high immune subtype, with higher immune cell infiltration, closer tumor-immune cell interactions, and upregulated IFN-signature expression in high-immune subtype. Determining expression levels of CD8B and ICOS facilitated this immune classification and prediction of patient prognosis. Finally, promoter DNA methylation contributed to different immune profiles of two subtypes by regulating immune-gene expression. There is comprehensive heterogeneity in the genome, transcriptome, and epigenome of multifocal ICC. On the basis of the less heterogeneous immune profile of ICC, we suggest an immune classification that stratifies patients' prognosis and may support personalized immunotherapy.